title: [The clinical analysis of corticosteroid ocular hypertension and corticosteroid glaucoma after photorefractive keratectomy].
abstract: OBJECTIVE
  To inquire into the incidence, clinical characteristics and therapeutic effects of corticosteroid hypertension and corticosteroid glaucoma after photorefractive keratectomy (PRK).
  
  
  METHODS
  The authors completed a follow up study on 1 590 eyes on which this procedure was performed and corticosteroid (0.1% fluoromethalone, FML) eye drops were applied 4 to 6 months post-operatively to observe intraocular pressure at 1, 3, 6, 12 and 24 months, and treated the eyes with increase of intraocular pressure.
  
  
  RESULTS
  Corticosteroid ocular hypertension or corticosteroid glaucoma occurred in 2.70% of 1 590 eyes. The intraocular pressure of the eyes was recovered to normal in all patients after treatments of stopping FML eye drops, using topical 0.5% timolol (or 0.5% levobunolol hydrochloride), taking diamox orally or receiving trabeculectomy.
  
  
  CONCLUSIONS
  Topical application of corticosteroid may cause corticosteroid hypertension and corticosteroid glaucoma after PRK, and visual function damage may occur in a few eyes. Under this situation, the corticosteroid eye drops should be stopped and glaucomatous treatment should be given.
authors.affiliation: Department of Ophthalmology, The Affiliated Changhai Hospital, The Second Military Medical University, Shanghai 200433.
authors.forename: C
authors.initials: C
authors.lastname: Li
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: C
authors.initials: C
authors.lastname: Huang
mesh_terms: D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000139:chemically induced* / Q000601:surgery; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D054018:Lasers, Excimer; D008297:Male; D009216:Myopia / Q000601:surgery; D009798:Ocular Hypertension / Q000139:chemically induced* / Q000601:surgery; D009883:Ophthalmic Solutions; D018903:Photorefractive Keratectomy / Q000009:adverse effects*; D011183:Postoperative Complications
chemical_list: D005938:Glucocorticoids; D009883:Ophthalmic Solutions